Pinebridge Investments LLC Makes New $104.75 Million Investment in Eli Lilly and Company $LLY

Key Points

• Pinebridge Investments LLC disclosed a new position in Eli Lilly, buying 97,473 shares worth about $104.75 million in the fourth quarter. The stake represents about 0.8% of Pinebridge’s portfolio and is its 26th-largest holding.
• Eli Lilly continues to attract strong institutional and analyst support, with hedge funds owning 82.53% of the stock and Wall Street maintaining a Moderate Buy consensus. The average price target currently stands at $1,227.
• The company reported strong quarterly results, beating estimates with $8.55 EPS and $19.8 billion in revenue, while revenue jumped 55.5% year over year. Lilly also recently announced a quarterly dividend of $1.73 per share, payable June 10.

Pinebridge Investments LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 97,473 shares of the company's stock, valued at approximately $104,752,000. Eli Lilly and Company comprises about 0.8% of Pinebridge Investments LLC's holdings, making the stock its 26th biggest holding.

Other institutional investors have also modified their holdings of the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after buying an additional 16 shares during the last quarter. 10Elms LLP lifted its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock worth $32,000 after buying an additional 24 shares during the last quarter. Finally, Miller Global Investments LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on LLY shares. Leerink Partners set a $1,119.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, May 26th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Friday. Wolfe Research restated an "outperform" rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an "overweight" rating in a research report on Friday, May 1st. Finally, Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,227.00.

Eli Lilly and Company Stock Up 0.7%

LLY stock opened at $1,133.15 on Friday. The company has a fifty day moving average price of $974.59 and a 200 day moving average price of $1,013.04. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,166.29. The company has a market cap of $1.07 trillion, a price-to-earnings ratio of 40.25, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company's revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is presently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark reversed its earlier exclusion and will now cover Eli Lilly’s Zepbound, a meaningful reimbursement win that could expand patient access and bolster obesity-drug sales. Article Title
• Positive Sentiment: WeightWatchers Med+ is now available through LillyDirect, reinforcing Lilly’s distribution ecosystem and strengthening its leadership in chronic weight management. Article Title
• Positive Sentiment: Lilly announced a new Phase 2b obesity trial for macupatide–eloralintide, adding another potential growth driver to its weight-loss pipeline beyond current GLP-1 products. Article Title
• Positive Sentiment: Jim Cramer highlighted Lilly as a potential winner against competitors, with attention on its new pill version of its weight-loss drug and broader competitive advantages. Article Title
• Positive Sentiment: Analysts and market commentary continue to frame LLY as a long-term winner, citing strong execution, deal-making, and diversification efforts beyond obesity drugs. Article Title
• Neutral Sentiment: Lilly also received coverage around its Phase 3 Libretto-432 cancer study and a $1.9 billion Ascidian partnership, both of which support the pipeline but are longer-term in nature. Article Title
• Neutral Sentiment: Broader health-care sector commentary and stock-screen articles were generally supportive, but they are less likely to be a direct driver of LLY’s move than the CVS and pipeline news. Article Title

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.